Showing 11-20 of 454 results
Helsinn Therapeutics (U.S.) Inc. invites proposals for Investigator Initiated Studies (IIS) and medical education. Helsinn may provide funding for medical education and research that is in line with its therapeutic areas of interest. Requests must include a cover letter that states a description of the grant activity, the program/activity title, start and end date of each act...
Helsinn out-licenses its products to commercial partners in its global distribution network while promoting and distributing to the cancer-care community in the US through our subsidiary Helsinn Therapeutics.
We understand that only the most dedicated researchers, world-class facilities, and highest standards in science, quality, and ethics, will deliver the results we need for our patients – and help fulfil more unmet needs. That’s why over the past five years we’ve reinvested 30% of our profits into our facilities and research and development. Our R&D capabilities are recognized w...
We’re committed to quality; it’s one of the core values that define how we work. Because we consistently upgrade our facilities and maintain them to the highest standards for producing medicines, we can be proud of our position as a global leader in the manufacture of medicines.
Helsinn Group operates through a unique business model of Integrated Licensing, focused on the in-licensing of Novel Chemical Entities (NCE) from R&D partners, and the out-licensing of its entire pipeline of products to a wide network of commercial partners. We have established a network covering approximately 190 countries, bringing together the brightest minds and motivated o...
Helsinn is committed to working with the US cancer-care community, and with this in mind, in 2009 Helsinn Therapeutics was established in New Jersey, USA, through the acquisition of a small biotech company and has now developed into a fully integrated oncology sales company. This important step in the company's development has made Helsinn’s first direct presence in the USA ter...
With more than 30 years of experience in classical Active Pharmaceutical Ingredients (APIs), and 15 years in High Potency Active Ingredients (HPAPIs), Helsinn has built a formidable reputation in the custom manufacture of these products. We manufacture our own products, those for our partners and those for third-party contracts, which virtual global partners to some of the worl...
We currently have over 70 valued partnerships covering approximately 190 countries worldwide, which help us optimize the commercial success of our pharmaceutical products worldwide.
Helsinn is at the 35th Annual JP Morgan Healthcare Conference taking place from January 9 to 13, 2017 in San Francisco, CA.
Patient Advocacy Groups protect the interests of cancer patients by helping them to receive appropriate and timely care, education, support and financial assistance, when needed. Helsinn works closely with, or has relationships with, the following groups: